You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞洲聯合基建控股(00711.HK)擬6400萬港元收購專門製造PET藥物放射性藥物製造商
格隆匯 10-20 22:46

格隆匯 10 月 20日丨亞洲聯合基建控股(00711.HK)公告,於2020年10月20日,買方Great Adventure Limited(公司間接全資附屬公司)與賣方Ample Honesty Limited訂立買賣協議,據此,買方有條件同意購買及賣方有條件同意出售Hong Kong Cyclotron Laboratories Limited全部已發行股本,代價為6400萬港元。

目標公司為一間於香港註冊成立有限公司,並由賣方全資擁有。目標公司主要從事製造正電子發射斷層掃描("PET")放射性藥物作醫療用途,例如氟化脱氧葡萄糖。

目標公司於2006年成立,為一間專門製造PET藥物的放射性藥物製造商,並經營香港最大的PET放射性藥物分銷網絡,為醫院及造影中心提供PET藥物。經考慮(i)由於公眾健康意識增強導致的潛在需求增長;及(ii)提升盈利能力,董事認為收購事項為集團提供極佳機會,以擴大業務規模並帶來多元化的收入來源。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account